Skip to main content

Table 1 Characteristics of the eligible studies

From: Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

Author Year Tumor stage Neoadjuvant chemotherapy TNBC pCR rate of TNBC non-TNBC pCR rate of non-TNBC OR (95% CI)
pCR no-pCR pCR no-pCR
Rouzier R [8] 2005 I, II, III 12 weeks of P followed by FAC 4 courses (weekly P (80 mg/m2) × 12 + FAC × 4 or 3 weekly P (225 mg/m2) × 4 + FAC × 4) 10 12 45.50% 11 49 18.30% 3.71 (1.28, 10.76)
Carey LA [1] 2007 II, III A 60 mg/m2 + C 600 mg/m2 every 2 weeks or 3 weeks for 4 cycles, either alone or as the first component of a sequential AC-taxane neoadjuvant regimen 9 25 26.50% 8 69 10.40% 3.10 (1.08, 8.93)
Goldstein NS [12] 2007 IIA to IIIC FAC every 3 weeks × 6 FEC every 3 weeks × 6 AC every 2 weeks (dose dense) × 4 then paclitaxel every 2 weeks (dose dense) × 4 AC every 3 weeks × 4 then P every 1 week × 4 12 9 57.10% 16 31 34.00% 2.58 (0.90, 7.41)
Keam B [13] 2007 II, III D (75 mg/m2 or 60 mg/m2) and A (60 mg/m2 or 50 mg/m2) by intravenous infusion every 3 weeks for 3 cycles 8 39 17.00% 3 95 3.10% 6.50 (1.64, 25.78)
Liedtke C [9] 2008 I, II, III FAC; FEC; weekly or once every 3 weeks P/D followed by FAC; weekly or once every 3 weeks P/D followed by FEC 57 198 22.40% 98 765 11.40% 2.25 (1.56, 3.23)
Bidard FC [14] 2008 I, II, III FEC (F 500 mg/m2, E 100 mg/m2, C 500 mg/m2) or FAC (F 500 mg/m2, A 60 mg/m2, C 500 mg/m2), every 3 weeks for 4 to 6 cycles 21 99 17.50% 7 166 4.00% 5.03 (2.06, 12.26)
Julka PK [15] 2008 IIA to IIIB 4 cycles (21 days) of Gem 1,200 mg/m2 + A 60 mg/m2, 4 cycles of Gem 1,000 mg/m2 plus Cis 70 mg/m2 7 7 50.00% 6 16 27.30% 2.67 (0.65, 10.88)
Sánchez-Muñoz A [16] 2008 II, III Schedule A: E 90 mg/m2 + C 600 mg/m2 d1 for 3 cycles followed by a second sequence with P 150 mg/m2 + Gem 2,500 mg/m2 d1 ± trastuzumab 2 mg/kg/week according to HER2 status Schedule B: A 40 mg/m2 d1 + P 150 mg/m2 + Gem (2,000 mg/m2) d2, 2 weekly for 6 cycles 14 10 58.30% 17 58 22.70% 4.78 (1.80, 12.66)
Sirohi B [17] 2008 M0 F 200 mg/m2 daily with E 60 mg/m2 and Cis 60 mg/m2 both repeating 3 weekly for 6 courses 1 5 16.70% 5 49 9.30% 1.96 (0.19, 20.26)
Darb-Esfahani S [18] 2009 T2 to 3, N0 to 2, M0 A 50 mg/m2 + D 75 mg/m2 every 14 days for 4 cycles or 4 cycles A 60 mg/m2 plus C 600 mg/m2 every 21 days followed by D 100 mg/m2 every 21 days for 4 cycles 8 25 24.20% 5 78 6.00% 4.99 (1.50, 16.65)
Sikov WM [19] 2009 IIA to IIIB Cb (AUG = 6) every 4 weeks and P 80 mg/m2 weekly for 16 weeks, and weekly trastuzumab was added for HER2(+) status 8 4 66.70% 16 25 39.00% 3.13 (0.81, 12.11)
Bhargava R [20] 2010 I, II, III Anthracycline-based therapy: AC, FEC; taxane-based therapy: T/P + Cb. In many cases a sequential combination of anthracycline and taxane was given: AC-T. The total number of cycles ranged from 4 to 10 with an average of 6 24 55 30.40% 24 256 8.60% 4.65 (2.46, 8.80)
Chang HR [21] 2010 II, III D (75 mg/m2) and Cb (AUC = 6) were administered every 3 weeks for 4 cycles. Patients with HER2(+) tumors were randomized to receive either additional weekly trastuzumab preoperatively or TC alone 6 5 54.50% 13 47 21.70% 4.34 (1.14, 16.51)
Chavez-Macgregor M [22] 2010 M0 Taxane administered: P 175 to 250 mg/m2 on d1, 3 weekly for 4 cycles; P 80 mg/m2 weekly for 12 doses; or D 100 mg/m2 on d1, 3 weekly for 4 cycles Anthracycline regimens (3 to 6 cycles): F 500 mg/m2, E 100 mg/m2 and C 500 mg/m2 on d1, d3 weekly; F 500 mg/m2 on d1, d4, E 75 mg/m2 and C 500 mg/m2 on d1, 3 weekly 95 395 19.40% 165 1419 10.40% 2.07 (1.57, 2.73)
Chen XS [23] 2010 T3 to 4, any N, M0;
any T, N2 to 3, M0
VE: V 25 mg/m2 d1, d8 + E 60 mg/m2 d1, d3 weekly; PCb: P 80 mg/m2 + Cb AUC = 2 d1, d8, d15, 4 weekly; CEF: C 500 mg/m2, E 75 mg/m2 and F 500 mg/m2 d1, 3 weekly; CTF: C 500 mg/m2, THP 50 mg/m2, and F 500 mg/m2 d1, 3 weekly; CEF➝T: D 75 mg/m2 d1, 3 weekly; ED: E 60 mg/m2 + D 75 mg/m2, 3 weekly 9 44 17.00% 19 153 11.00% 2.07 (0.86, 4.96)
Huober J [24] 2010 I, II, III 6 to 8 cycles of TAC (D 75 mg/m2, A 50 mg/m2, C 500 mg/m2 on d1, every 3 weeks) or 2 cycles of TAC followed by four cycles of V 25 mg/m2 on d1, d8 + capecitabine 1,000 mg/m2 orally twice a day on d1 to d14 every 3 weeks 198 311 38.90% 147 820 15.20% 3.55 (2.77, 4.56)
Kim SI [25] 2010 M0 A (50 mg/m2, d1) + D (75 mg/m2, d1) chemotherapy (AT) every 3 weeks for 3 cycles 16 60 21.10% 10 181 5.20% 4.83 (2.08, 11.21)
Pierga JY [26] 2010 II, III E (75 mg/m2) + C (750 mg/m2) intravenously every 3 weeks for 4 cycles followed by D (100 mg/m2) every 3 weeks for 4 cycles with or without trastuzumab (8 mg/kg at first infusion then 6 mg/kg) every 3 weeks 23 55 29.50% 14 57 19.70% 1.70 (0.80, 3.64)
Straver ME [27] 2011 T1 to 3, N0 to 2, M0 AC (6 cycles of A 60 mg/m2 and C 600 mg/m2 every 3 weeks) or AD (6 cycles of A 50 mg/m2 and D 75 mg/m2, every 3 weeks) 16 41 28.10% 13 181 6.70% 5.43 (2.43, 12.17)
Bernsdorf M [28] 2011 T2 to 3, N0 to 3b, M0 4 cycles of EC (E 90 mg/m2 and C 600 mg/m2) plus 12 weeks of daily treatment with gefitinib 250 mg or EC plus 12 weeks’ treatment with placebo. Chemotherapy was administered every 3 weeks 12 70 14.60% 1 47 2.10% 8.06 (1.01, 64.06)
Iwata H [29] 2011 T1c to 3, N0, M0; T1 to 3, N1, M0 4 cycles of D (75 mg/m2) administered intravenously every 21 days followed by 4 cycles of FEC (F 500 mg/m2, E 100 mg/m2 and C 500 mg/m2) administered intravenously on d1 every 21 days before surgery 14 15 48.30% 16 84 16.00% 4.90 (1.99, 12.09)
Loo CE [30] 2011 T2 to 4, N1 to 3, M0 Either ER(+) or (–), received 6 courses of AC, administered in a dose-dense schedule (every 2 weeks). A minority received 6 courses of capecitabine + D or doxorubicin + D 16 41 28.10% 22 119 15.60% 2.11 (1.01, 4.40)
Medioni J [31] 2011 II, III Six 2-weekly courses of Gem 1,000 mg/m2 + D 75 mg/m2 on d1, d15 and V 25 mg/m2 + E 100 mg/m2 on d29, d43. Patients with an objective response on d56 then received another cycle of Gem + D on d57 and V + E on d71 9 13 40.90% 7 43 14.00% 4.25 (1.32, 13.65)
Nakahara H [32] 2011 T1 to 4 HER2(–) tumors started with CE (E 75 mg/m2 × d1 + C 100 mg × daily for 14 days with 7 days’ rest) for 4 or 6 cycles. HER2(+) tumors initiated with CE (E 90 mg/m2 × d1 or E 50 mg/m2 × d1, d8 and C 100 mg × daily for 14 days with 7 days’ rest) 5 13 27.80% 3 65 4.40% 8.33 (1.77, 39.27)
Wu J [33] 2011 II, III P (175 mg/m2) or D (75 mg/m2) + doxorubicin (60 mg/m2) or E (90 mg/m2) every 21 days for a total of 4 cycles 14 40 25.90% 24 171 12.30% 2.49 (1.19, 5.25)
Le Tourneau C [34] 2012 II, III 4 cycles of intensified FAC (A 70 mg/m2 d1, C 700 mg/m2 d1 + d8, and F 700 mg/m2 d1 to d5) every 3 weeks 9 10 47.40% 3 30 9.10% 9.00 (2.03, 39.93)
Ono M [35] 2012 II, III Anthracycline-based regimen (AC: A 60 mg/m2 + C 600 mg/m2 or CEF: C 600 mg/m2 + E 100 mg/m2 + F 600 mg/m2) Taxane-based regimen (weekly P 80 mg/m2 or triweekly D 75 mg/m2) Anthracycline and taxane sequentially or concurrently (A 50 mg/m2 + D 60 mg/m2, AC or CEF followed by weekly P or triweekly D) 26 66 28.30% 9 70 11.40% 3.06 (1.34, 7.02)
  1. A, adriamycin; C, cyclophosphamide; Cb, carboplatin; CI, confidence interval; Cis, cisplatin; d, day; D, docetaxel; E, epirubicin; F, 5-fluorouracil; Gem, gemcitabine; HER2, human epidermal growth factor receptor 2; OR, odds ratio; P, paclitaxel; pCR, pathologic complete response; THP, pirarubicin; TNBC, triple-negative breast cancer; V, vinorelbine; T, Taxane/Taxotere; AUC, area under the curve.